Design Therapeutics Inc.

NASDAQ: DSGN · Real-Time Price · USD
5.35
0.19 (3.68%)
At close: Aug 15, 2025, 3:59 PM
5.33
-0.37%
After-hours: Aug 15, 2025, 04:04 PM EDT

Design Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a 588K n/a n/a n/a 838K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
152K 159K 149K 153K 151K 143K 138K 137K 143K 139K 135K 122K 113K 96K 82K 31K 12K 4K
Gross Profit
-152K -159K 294K -153K -151K -143K -138K -137K -143K -139K -135K -122K -113K -96K -82K -31K -12K -4K
Operating Income
-21.57M -20.42M -16.69M -16.25M -15.04M -14.4M -15.12M -18.82M -22.6M -21.65M -19.39M -19.19M -15.64M -13.37M -11.13M -11.34M -7.69M -5.68M
Interest Income
2.49M 2.7M 3.04M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-19.08M -17.71M -13.65M -13.04M -11.79M -11.11M -11.84M -15.79M -19.94M -19.29M -17.34M -17.7M -15M -13.27M -11.06M -11.32M -7.64M -5.51M
Net Income
-19.08M -17.71M -13.65M -13.04M -11.79M -11.11M -11.84M -15.79M -19.94M -16.94M -15.16M -16.22M -14.36M -13.16M -11.06M -11.32M -7.64M -5.51M
Selling & General & Admin
5.83M 5.04M 4.54M 4.37M 4.53M 4.6M 4.11M 5.57M 5.53M 5.92M 5.14M 4.89M 4.34M 4.61M 3.79M 2.8M 2.66M 1.8M
Research & Development
15.74M 15.38M 12.16M 11.88M 10.37M 9.66M 10.87M 13.26M 17.06M 15.73M 14.26M 14.3M 11.29M 8.76M 7.34M 8.54M 5.03M 3.88M
Other Expenses
n/a n/a -149K n/a n/a n/a n/a -137K n/a n/a n/a n/a n/a 105K 62K 19K 51K n/a
Operating Expenses
21.57M 20.42M 16.55M 16.25M 14.89M 14.26M 14.98M 18.68M 22.6M 21.65M 19.39M 19.19M 15.64M 13.37M 11.13M 11.34M 7.69M 5.68M
Interest Expense
n/a n/a n/a n/a n/a n/a 129K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a 76K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
21.57M 20.42M 16.69M 16.25M 15.04M 14.4M 15.12M 18.82M 22.6M 21.65M 19.39M 19.19M 15.64M 13.37M 11.13M 11.34M 7.69M 5.68M
Income Tax Expense
n/a n/a n/a n/a n/a n/a n/a n/a 10.91K -2.36M -2.18M -1.49M -640K -105K -62K n/a n/a n/a
Shares Outstanding (Basic)
56.86M 56.76M 56.68M 56.62M 56.56M 56.49M 56.15M 55.99M 55.95M 55.91M 55.86M 55.78M 55.67M 55.51M 55.36M 55.16M 55.08M 17.63M
Shares Outstanding (Diluted)
56.86M 56.76M 56.68M 56.62M 56.56M 56.49M 56.15M 55.99M 55.95M 55.91M 55.86M 55.78M 55.67M 55.51M 55.36M 55.16M 55.08M 17.63M
EPS (Basic)
-0.34 -0.31 -0.24 -0.23 -0.21 -0.2 -0.21 -0.28 -0.36 -0.3 -0.27 -0.29 -0.26 -0.24 -0.2 -0.21 -0.14 -0.31
EPS (Diluted)
-0.34 -0.31 -0.24 -0.23 -0.21 -0.2 -0.21 -0.28 -0.36 -0.3 -0.27 -0.29 -0.26 -0.24 -0.2 -0.21 -0.14 -0.31
EBITDA
-21.57M -20.26M -16.55M -16.09M -14.89M -14.26M -14.98M -18.68M -22.46M -21.52M -19.27M -19.08M -15.55M -13.29M -11.04M -11.31M -7.67M -5.68M
EBIT
-19.08M -20.42M -16.69M -16.25M -15.04M -14.4M -15.12M -18.82M -22.6M -21.65M -19.39M -19.19M -15.64M -13.37M -11.13M -11.34M -7.69M -5.68M
Depreciation & Amortization
152K 159K 149K 153K 151K 143K 138K 137K 143K 139K 135K 122K 113K 96K 82K 31K 12K 4K